Save time and get answers to complex questions with AI chat
Symbravo ingredients mechanism of action?Stribild expiry date?Is clarinex off patent?When is the expected fda decision date for apotex's ruxolitinib resubmission?Chlorpheniramine cost?
See the DrugPatentWatch profile for Daliresp
Daliresp (roflumilast) is prescribed to lower the risk of COPD exacerbations in people with severe COPD associated with chronic bronchitis who have frequent exacerbations (as defined in the product’s prescribing information) [1].
Daliresp is aimed at people with: - Severe COPD - Chronic bronchitis symptoms - A history of frequent exacerbations despite standard therapy [1]
No. Daliresp is indicated for COPD, not asthma [1].
Daliresp is not a rescue medication for acute shortness-of-breath episodes. It is used for maintenance to help reduce the likelihood of exacerbations over time [1].
People often search whether roflumilast (Daliresp) is used for: - Emphysema without chronic bronchitis: the indication specifically targets COPD with chronic bronchitis and frequent exacerbations [1] - “Frequent exacerbations” definition: the prescribing information ties this to exacerbation frequency in the clinical trial/program context used for labeling [1]
[1] https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=...
Other Questions About Daliresp :